ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
Abstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheumatology Highlight Potential Value of TAVNEOS™ (avacopan)GlobeNewsWire • 11/04/21
ChemoCentryx to Hold Third Quarter 2021 Financial Results Conference Call on Tuesday, November 9, 2021GlobeNewsWire • 11/02/21
ChemoCentryx (CCXI) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 11/01/21
ChemoCentryx (CCXI) Soars 5.4%: Is Further Upside Left in the Stock?Zacks Investment Research • 10/08/21
ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drugMarket Watch • 10/08/21
ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated VasculitisGlobeNewsWire • 10/08/21
ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated VasculitisGlobeNewsWire • 09/27/21